Novel glycoproteins and methods of use thereof

• US 20050069914A1
• Filed: 03/25/2004
• Published: 03/31/2005
• Est. Priority Date: 05/08/2000
• Status: Abandoned Application

• Current Assignee: Chaomei He, Christie A. Kelton, Nabil El Tayar, Robert K. Campbell, Susan Kiernan
• Original Assignee: Chaomei He, Christie A. Kelton, Nabil El Tayar, Robert K. Campbell, Susan Kiernan
• Inventors: Kiernan, Susan, Kelton, Christie A., Campbell, Robert K., He, Chaomei, El Tayar, Nabil
• Application Number:
  US10/811,081
• Publication Number:
  US 20050069914A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07K 14/575 Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C07K14/665, e.g. corticotropin C07K14/695
• CPC Class Codes: C07K 14/59 Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
• CPC Class Codes: C07K 16/26 against hormones ; against hormone releasing or inhibiting factors
• CPC Class Codes: C07K 2317/34 Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Abstract

The present invention provides novel isolated ARP/BRP polynucleotides and the membrane-associated or secreted polypeptides encoded by the ARP/BRP polynucleotides. Also provided are ARP and BRP protein multimers. Further provided are the antibodies that immunospecifically bind to a ARP/BRP polypeptide or any derivative, variant, mutant or fragment of the ARP/BRP polypeptide, a ARP/BRP multimer polynucleotide or antibody. The invention additionally provides methods in which the ARP/BRP polypeptide, multimer, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, e.g. reproductive disorder, as well as to other uses.

Claims

1-40. -40. (canceled)

41. An isolated polynucleotide encoding a polypeptide that is at least 70% similar to SEQ ID NO:

2.

43. The polynucleotide of claim 41 or 42 which is at least 90, preferably 95% similar to SEQ ID NO:

2.

44. The polynucleotide of claims 41-42 said polypeptide comprising the amino acid Cys at positions corresponding to amino acid positions 35, 49, 59 and 63 of SEQ ID NO:

2.

45. The polynucleotide of claim 44 with the amino acid Cys at positions corresponding to amino acid positions 83, 98, 114, 116, 119 and 126 of SEQ ID NO:

2.

46. The polynucleotide according to claim 45, said polynucleotide comprising the sequence SEQ ID NO:

1.

47. The polynucleotide according to claim 44, said polynucleotide comprising the sequence SEQ ID NO:

1 or the sequence extending from nucleotides 55-385 of SEQ ID NO;

1.

48. A recombinant expression vector comprising the DNA according to claims 41-47.

49. Polypeptide encoded by the polynucleotide according to claims 41-47 or the expression vector according to claim 48.

50. A cell transfected with DNA according to claims 41-47 or the expression vector according to claim 48.

52. A method to produce the polypeptide of claim 49 the method comprising culturing the cells of claim 51 under conditions wherein said protein is produced and recovering said protein from the culture.

53. A pharmaceutical composition comprising a polypeptide according to claim 49 in admixture with a pharmaceutically acceptable carrier.

42. An isolated polynucleotide encoding a mature polypeptide that is at least 70% similar to the mature polypeptide part of SEQ ID NO:

2.